Nick Medjeral-Thomas

KRUK/IC clinical research fellow, nephrology and GIM dr, proud dad, spectacular husband. None of this is clinical advice. Views often inspired by clever people

[Nick Medjeral-Thomas @NickRhysMT]

Incredible work by @jack_gisby
, Jimmy Peters and many others @ImperialImmuno @imperialcollege @ImperialNHS renal and transplant centre @clclarke227
@mkwillicombe https://t.co/95hnbED7lS

[Nick Medjeral-Thomas @NickRhysMT]

This describes our experience managing #haemodialysis patients with #COVIDー19
@ImperialNHS community dialysis unit incl risk factors for deterioration and (zero) staff infections
https://t.co/lF58RDe0Qy

[Candice Clarke @clclarke227]

Pleased to see our paper available preprint. Huge collaborative effort from clinicians, scientists, dialysis nurses and patients @imperialcollege @ImperialImmuno @ImperialNHS @mkwillicombe @Maria_Prend @stephenmcadoo @NickRhysMT

[Nick Medjeral-Thomas @NickRhysMT]

Proud to be part of this huge effort from scientists and clinicians to detail longitudinal proteomic profiles of end-stage kidney disease patients with #COVID19 #medRxiv @ImperialImmuno @ImperialNHS @clclarke227 @jack_gisby

medrxiv viewer https://t.co/o8KXSUybor

[Nick Medjeral-Thomas @NickRhysMT]

Thank you for hosting @NephJC #NephJC

[Nick Medjeral-Thomas @NickRhysMT]

@HotKidneyAction @NephJC Was a multicentre trial - No difference in findings in non-Imperial College vs Imperial College patients #NephJC

[Nick Medjeral-Thomas @NickRhysMT]

@NephJC And when you discuss the evidence with your patient and consider their opinion too #NephJC

[Nick Medjeral-Thomas @NickRhysMT]

@HotKidneyAction @NephJC Read correctly. I think you're right; it prob contributed. We were trying to compare the two regimens, not identical treatment durations. Interesting that even a long (ish) course of treatment with Tac was well tolerated #NephJC

[Jelle B @JelleB12]

What to do with the relapses. Rechallenge with Tac? #nephjc

[Nick Medjeral-Thomas @NickRhysMT]

@carlo_alfieri @NephJC Doses were similar but because multicentre, indvidual agents and doses used varied and statistical comparison difficult. We didn't insist on maximal RAASI. Clinically, we don't max RAASI before starting pred or tac in MCD #NephJC

[Nick Medjeral-Thomas @NickRhysMT]

@HotKidneyAction @sarah_gleeson_ @NephJC @goKDIGO 'If' you move away #NephJC

[Nick Medjeral-Thomas @NickRhysMT]

@HotKidneyAction @sarah_gleeson_ @NephJC @goKDIGO You might have DM @sarah_gleeson_ to get an honest answer😉 #NephJC

[Megan Griffith @megan_griffith1]

Patients themselves often ask if there's an alternative an alternative to steroids. #NephJC

[Nick Medjeral-Thomas @NickRhysMT]

#NephJC. Nick Medjeral-Thomas. MinTac author. No other COI

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

MinTac Trial: Tacrolimus monotherapy can be an effective alternative treatment for patients wishing to avoid steroid therapy for minimal change disease ca. 2020 from @CJASN @NickRhysMT @megan_griffith1 @IgAN_JBarratt @neilturn @Profcpusey #Nephpearls
👉🏼 https://t.co/NO39OUW8EW

[Nick Medjeral-Thomas @NickRhysMT]

@ThePeanutKidney @aishaikh @Ashidotic @renalpathdoc @SethiRenalPath @toates_19 Yes, can detect by IP, but sensitivity meant to be better with IF. The extra step is the pronase antigen detection, but if done correctly, IP and IF should work. You can always refer slides to Terry Cook who does this routinely on most C3G pts, esp those over 50yrs age

[Swapnil Hiremath @hswapnil.medsky.social @hswapnil]

Tacrolimus works as well as steroids for adult minimal change disease, from @NickRhysMT & @megan_griffith1
Day 1 #KidneyWk highlights

[Nick Medjeral-Thomas @NickRhysMT]

Glomerular complement deposition, in particular FHR5. Next 😉

[Stephen McAdoo @stephenmcadoo]

I’m convinced! From Famine to Feast - clinical trials in #IgAN from Dana Rizk at @ASNKidney #KidneyWk. But how do we select and stratify our patient for all these competing studies? @NickRhysMT @IgAN_JBarratt

[Ruth Pepper @RealDr_Pepper]

#KidneyWk #MinimalChange groundbreaking study showing it is possible to avoid steroids in patients with minimal change

[Juan Carlos Q Velez @VelezNephHepato]

Grilling them? Ha, nah, more like praising them. Important work from @megan_griffith1 and @NickRhysMT providing an efficacious alternative to high dose steroids for minimal change podocytopathy. @LGlomcon #KidneyWk